117 related articles for article (PubMed ID: 3103282)
1. Monoclonal anti-IL-2 receptor antibody in primate renal transplantation.
Shapiro ME; Kirkman RL; Reed MH; Puskas JD; Mazoujian G; Letvin NL; Carpenter CB; Milford EL; Waldmann TA; Strom TB
Transplant Proc; 1987 Feb; 19(1 Pt 1):594-8. PubMed ID: 3103282
[No Abstract] [Full Text] [Related]
2. Prolongation of primate renal allografts with anti-Tac monoclonal antibody.
Reed MH; Shapiro ME; Strom TB; Milford EL; Carpenter CB; Letvin NL; Waldmann TA; Kirkman RL
Curr Surg; 1988; 45(1):28-30. PubMed ID: 3126026
[No Abstract] [Full Text] [Related]
3. Immunosuppression with an anti-IL-2 receptor monoclonal antibody in a baboon renal allograft model.
Hayes JM; Spencer W; Valenzuela R; Caulfield M; Novick AC
Transplant Proc; 1989 Feb; 21(1 Pt 1):1006-9. PubMed ID: 2650061
[No Abstract] [Full Text] [Related]
4. Anti-TAC MOAB prolongs renal allografts in cynomolgus monkeys.
Reed MH; Shapiro ME; Strom TB; Carpenter CB; Letvin NL; Reimann K; Weinberg DS; Waldmann TA; Kirkman RL
Transplant Proc; 1989 Feb; 21(1 Pt 1):1028-30. PubMed ID: 2650064
[No Abstract] [Full Text] [Related]
5. Functional blocking of the interleukin-2 receptor (IL-2R) may be important in the efficacy of IL-2R antibody therapy.
Tellides G; Dallman MJ; Kupiec-Weglinski JW; Diamantstein T; Morris PJ
Transplant Proc; 1987 Oct; 19(5):4231-3. PubMed ID: 3118538
[No Abstract] [Full Text] [Related]
6. Phenotypic and functional analysis of kidney infiltrating T cells escaping monoclonal antibody treatment in primate renal transplantation.
Nocera A; Cosimi AB; Colvin RB; Gesner ML; Fuller TC
Transplant Proc; 1988 Apr; 20(2):205-6. PubMed ID: 3129830
[No Abstract] [Full Text] [Related]
7. Prophylactic treatment of human kidney allograft recipients with a monoclonal antibody (33B3.1) directed against interleukin 2 receptor.
Peyronnet P; Le Mauff B; Hourmant M; Cantarovich D; Dubigeon P; Olive P; Mawas C; Delaage M; Hirn J; Jacques Y
Transplant Proc; 1988 Apr; 20(2):300-2. PubMed ID: 3129836
[No Abstract] [Full Text] [Related]
8. The role of a primate model of renal transplantation in the development of new monoclonal antibodies.
Shapiro ME; Reed MH; Strom TB; Carpenter CB; Milford EL; Kirkman RL
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):58-60. PubMed ID: 2816938
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporine potentiates the immunosuppressive effects of anti-interleukin 2 receptor monoclonal antibody therapy.
Kupiec-Weglinski JW; Hahn HJ; Kirkman RL; Volk HD; Mouzaki A; DiStefano R; Tellides G; Dallman M; Morris PJ; Strom TB
Transplant Proc; 1988 Apr; 20(2 Suppl 2):207-16. PubMed ID: 3129841
[No Abstract] [Full Text] [Related]
10. Synergistic interaction of cyclosporine A with interleukin 2 receptor monoclonal antibody therapy.
Tellides G; Dallman MJ; Morris PJ
Transplant Proc; 1988 Apr; 20(2 Suppl 2):202-6. PubMed ID: 3129840
[No Abstract] [Full Text] [Related]
11. Mechanism of action of interleukin-2 receptor (IL-2R) monoclonal antibody (MAb) therapy: target cell depletion or inhibition of function?
Tellides G; Dallman MJ; Morris PJ
Transplant Proc; 1989 Feb; 21(1 Pt 1):997-8. PubMed ID: 2650306
[No Abstract] [Full Text] [Related]
12. A monoclonal anti-tac antibody may interfere with receptor binding of interleukin 2.
Taniguchi N; Miyawaki T; Yachie A
Lymphokine Res; 1982; 1(4):107-12. PubMed ID: 6097775
[No Abstract] [Full Text] [Related]
13. Treatment with anti-interleukin-2 receptor monoclonal antibody.
Strom TB; Gaulton GN; Kelley VE; Diamanstein T; Kupiec-Weglinski J; Tilney NL; Kirkman RL
Prog Clin Biol Res; 1986; 224():227-38. PubMed ID: 3099309
[No Abstract] [Full Text] [Related]
14. Early experience with anti-Tac in clinical renal transplantation.
Kirkman RL; Shapiro ME; Carpenter CB; Milford EL; Ramos EL; Tilney NL; Waldmann TA; Zimmerman CE; Strom TB
Transplant Proc; 1989 Feb; 21(1 Pt 2):1766-8. PubMed ID: 2652578
[No Abstract] [Full Text] [Related]
15. Effect of treatment with anti-IL-2-receptor monoclonal antibody and CsA on peripheral nerve allograft rejection.
Grochowicz PM; Romaniuk A; Diamantstein T; Olszewski WL
Transplant Proc; 1987 Oct; 19(5):4302-3. PubMed ID: 3118540
[No Abstract] [Full Text] [Related]
16. OKT4A monoclonal antibody immunosuppression of cynomolgus renal allograft recipients.
Cosimi AB; Delmonico FL; Wright JK; Wee SL; Preffer FI; Bedle M; Colvin RB
Transplant Proc; 1991 Feb; 23(1 Pt 1):501-3. PubMed ID: 1990600
[No Abstract] [Full Text] [Related]
17. Studies on T lymphocyte activation. II. Monoclonal antibody inhibiting the capacity of rat T lymphoblasts to absorb and to respond to IL-2: an anti-IL-2 receptor antibody?
Osawa H; Diamantstein T
Immunology; 1983 Mar; 48(3):617-21. PubMed ID: 6600707
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of anti-interleukin 2 receptor and anti-L3T4 antibodies on delayed type hypersensitivity: the role of complement and epitope.
Kelley VE; Gaulton GN; Strom TB
J Immunol; 1987 May; 138(9):2771-5. PubMed ID: 3106488
[TBL] [Abstract][Full Text] [Related]
19. Treatment of presensitization with IL-2 receptor antibody plus alloantigen.
Tyler JD; Wierwille SL; Goldman MH
Transplant Proc; 1989 Feb; 21(1 Pt 1):1010-2. PubMed ID: 2650062
[No Abstract] [Full Text] [Related]
20. Humanized antibody directed to the IL-2 receptor beta-chain prolongs primate cardiac allograft survival.
Tinubu SA; Hakimi J; Kondas JA; Bailon P; Familletti PC; Spence C; Crittenden MD; Parenteau GL; Dirbas FM; Tsudo M
J Immunol; 1994 Nov; 153(9):4330-8. PubMed ID: 7930631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
